3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Not yet recruiting
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Small Cell Lung Carcinoma
1
Sarcoma
1
Leukemia, Myeloid, Acute
1
Ichthyosis, X-Linked
1
Glioblastoma
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Temozolomide
41
Radiotherapy
19
Radiation
12
Nivolumab
10
pembrolizumab
8
Magnetic Resonance Spectroscopy
8
Bevacizumab
7
Specimen Handling
6
poly ICLC
4
atezolizumab
4
Lomustine
4
Ipilimumab
4
Surgical Procedures, Operative
3
Photons
3
Immunoglobulin G
3
Disulfides
3
Cyclophosphamide
3
veliparib
2
sargramostim
2
rocakinogene sifuplasmid
2
olaparib
2
niraparib
2
Transurethral Resection of Bladder
2
Surveys and Questionnaires
2
Standard of Care
2
Radiotherapy, Intensity-Modulated
2
Radiosurgery
2
OKN 007
2
Mycophenolic Acid
2
Metformin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Glioblastoma
×
ADI PEG20
×
Clear all
NCT04587830
2025-08-26
GBM
Polaris Group
Phase 2
Active not recruiting
100 enrolled